Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 14/20 | 0.36 |
| ▸ | CNR1 | P21554 | 6/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139223 | 0.99 | CNR2 (0.36) | EPHX2CNR2CNR1HSD11B1NPY5R | |
| SCHEMBL4145642 | 0.89 | EPHX2 (0.42) | EPHX2CNR2CNR1HSD11B1 | |
| SCHEMBL4140796 | 0.89 | CNR2 (0.36) | EPHX2CNR2CNR1HSD11B1 | |
| SCHEMBL4130512 | 0.88 | EPHX2 (0.41) | EPHX2CNR2CNR1HSD11B1NPY5R | |
| SCHEMBL4135746 | 0.88 | CNR2 (0.39) | EPHX2CNR2CNR1 | |
| SCHEMBL4139936 | 0.88 | CNR2 (0.37) | EPHX2CNR2CNR1HSD11B1 | |
| SCHEMBL4135415 | 0.87 | CNR2 (0.35) | EPHX2CNR2CNR1HSD11B1 | |
| SCHEMBL4137114 | 0.86 | CNR2 (0.36) | EPHX2CNR2CNR1HSD11B1 | |
| SCHEMBL5429673 | 0.86 | CNR2 (0.36) | EPHX2CNR2CNR1HSD11B1 | |
| SCHEMBL5439595 | 0.85 | CNR2 (0.37) | EPHX2CNR2CNR1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | EPHX2 2285/4885CNR2 57/4885CNR1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.